Drug Type CAR-T |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD276 inhibitors(CD276 antigen inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Aleta Biotherapeutics, Inc.Startup |
Active Organization Aleta Biotherapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Neoplasms | Preclinical | US | Aleta Biotherapeutics, Inc.Startup | - |